spacer
home > ict > winter 2020 > comparator sourcing in clinical studies (part one of two)
PUBLICATIONS
International Clinical Trials

Comparator Sourcing in Clinical Studies (Part One of Two)




Choosing the right comparator supplier is becoming increasingly important to sponsor companies conducting clinical trials; drug development companies are constantly having to jump through narrower hoops, held higher each year by regulators. Costs to maintain drug integrity throughout the supply chain have risen exponentially over the last decade, and R&D budgets are being slashed like sacrificial lambs in homage to the great God: shareholder value. Mergers and acquisitions, and their resulting layoffs, combined with an ever-increasing number of eager, educated young professionals entering the life science employment sector has created a culture of fear in existing pharmaceutical employees who know that theirs is most definitely not a ‘job for life’. Clinical teams are under constant pressure to execute trials faster, compliantly, more effectively, with greater efficiency and transparency, with minimal risk, and for less money. Oh, and did I mention they have to plan everything at least 18 months in advance, be ready to adapt to any disaster on the turn of a dime, navigate an ever-changing regulatory landscape, but plan and manage any change before it happens? Trust me when I tell you that Ethan Hunt had it easy compared to the trials and tribulations of the average clinical trial supply chain manager. I am sure that countless numbers of these unsung heroes and heroines dream of one day running off to the circus to engage in the slightly less challenging career of juggling chainsaws. Pharma has evolved into a fast-changing environment that has typically feared change of all kinds, regardless of how much money it pumps into change management training for its people. The problem we are facing is that clinical supply chains and comparator drug distribution channels are changing dramatically and, therefore, so must our sourcing models to ensure that study drugs are accessible to patients enrolling in modern day clinical trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Toby Watkins is the Founder and Managing Director of a Swiss-based clinical trial supplies consultancy firm, CTSS, that helps sponsors identify, validate, and manage vendor companies across the clinical trial supply value chain. Over the last decade, Toby has worked on global comparator sourcing programmes helping sponsors source comparator drugs, ancillaries, and reference products and identify their vendors in over 30 countries around the globe. Prior to entering the clinical arena, he worked on named-patient and managed access programmes in emerging markets. Toby has had the privilege of working with many of the world’s innovators, comparator sourcing companies, CROs, CMOs, biotechs, Big Pharma companies, and their suppliers at every stage of drug development across multiple indications.
toby.watkins@clinicaltrialsupplysolutions.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement